Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis

We retrospectively reviewed data from 123 patients (KIT exon 11 mutated) who received sunitinib or dose-escalated imatinib as second line. All patients progressed on imatinib (400 mg/die) and received a second line treatment with imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 off or 37.5...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Vincenzi, Bruno, Nannini, Margherita, Fumagalli, Elena, Bronte, Giuseppe, Frezza, Anna Maria, De Lisi, Delia, Ceruso, Mariella Spalato, Santini, Daniele, Badalamenti, Giuseppe, Pantaleo, Maria Abbondanza, Russo, Antonio, Tos, Angelo Paolo Dei, Casali, Paolo, Tonini, Giuseppe
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2015
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342487/
https://ncbi.nlm.nih.gov/pubmed/26416414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.5136
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы